[go: up one dir, main page]

WO2006032053A3 - Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds - Google Patents

Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds Download PDF

Info

Publication number
WO2006032053A3
WO2006032053A3 PCT/US2005/033421 US2005033421W WO2006032053A3 WO 2006032053 A3 WO2006032053 A3 WO 2006032053A3 US 2005033421 W US2005033421 W US 2005033421W WO 2006032053 A3 WO2006032053 A3 WO 2006032053A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
vitamin
methods
related compounds
treating symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/033421
Other languages
French (fr)
Other versions
WO2006032053A2 (en
Inventor
Aharon Schwartz
David Ladkani
Zeev Mazor
Anat Achiron
Irit Pinchasi
Dina Kofler
Liat Hayardeny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to CA002580564A priority Critical patent/CA2580564A1/en
Priority to EP05798310A priority patent/EP1796680A2/en
Publication of WO2006032053A2 publication Critical patent/WO2006032053A2/en
Publication of WO2006032053A3 publication Critical patent/WO2006032053A3/en
Priority to IL181762A priority patent/IL181762A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention discloses a method of alleviating a symptom of multiple sclerosis in a human subject comprising administering to the human subject in need thereof a dose of a calciferol compound effective to alleviate the symptom of multiple sclerosis, alone or with another therapeutic agent.
PCT/US2005/033421 2004-09-14 2005-09-14 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds Ceased WO2006032053A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002580564A CA2580564A1 (en) 2004-09-14 2005-09-14 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
EP05798310A EP1796680A2 (en) 2004-09-14 2005-09-14 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
IL181762A IL181762A0 (en) 2004-09-14 2007-03-07 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60965104P 2004-09-14 2004-09-14
US60/609,651 2004-09-14
US62364904P 2004-10-28 2004-10-28
US62374404P 2004-10-28 2004-10-28
US60/623,744 2004-10-28
US60/623,649 2004-10-28
US69725805P 2005-07-06 2005-07-06
US60/697,258 2005-07-06

Publications (2)

Publication Number Publication Date
WO2006032053A2 WO2006032053A2 (en) 2006-03-23
WO2006032053A3 true WO2006032053A3 (en) 2006-09-08

Family

ID=36060740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033421 Ceased WO2006032053A2 (en) 2004-09-14 2005-09-14 Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Country Status (4)

Country Link
EP (1) EP1796680A2 (en)
CA (1) CA2580564A1 (en)
IL (1) IL181762A0 (en)
WO (1) WO2006032053A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0513984D0 (en) * 2005-07-07 2005-08-17 Teva Pharma Dosage form
WO2009097614A1 (en) * 2008-02-01 2009-08-06 Wisconsin Alumni Research Foundation Methods of treating multiple sclerosis by administering pulse dose calcitrol

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6369099B1 (en) * 1998-05-21 2002-04-09 Wisconsin Alumni Research Foundation Method of locking 1 α-OH of vitamin D compounds in axial orientation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6369099B1 (en) * 1998-05-21 2002-04-09 Wisconsin Alumni Research Foundation Method of locking 1 α-OH of vitamin D compounds in axial orientation

Also Published As

Publication number Publication date
IL181762A0 (en) 2007-07-04
CA2580564A1 (en) 2006-03-23
WO2006032053A2 (en) 2006-03-23
EP1796680A2 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2007131154A3 (en) Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2003097050A3 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
WO2005004854A3 (en) Use of betaine for treating arteritis
WO2005020908A3 (en) Selective inhibitors of stat-3 activation and uses thereof
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
WO2008036733A3 (en) Methods for treatment of vesicle transport disorders
WO2006032053A3 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 181762

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2580564

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005798310

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005798310

Country of ref document: EP